IGF1 and prostate carcinoma: Since there was a general trend towards a positive association of serum 25(OH)D with prostate cancer risk among men with higher levels of IGF analytes in the placebo arm, but a decreased risk among men in the finasteride arm, finasteride treatment and IGF concentration together may be important modifiers of the association of vitamin D with prostate cancer risk.